ArticlePloS one2015
Epstein-Barr Virus MicroRNA Expression Increases Aggressiveness of Solid Malignancies.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Immune hub genes and a proof-of-concept prognostic signature in EBV-associated gastric carcinoma.iScience · 2026Article
- The role of microRNAs in the gastric cancer tumor microenvironment.Molecular cancer · 2024Review
- Incidental discovery of a Hodgkin lymphoma synchronous to a papillary thyroid carcinoma.Clinical case reports · 2022Article
- Bacterial Diversity Correlates with Overall Survival in Cancers of the Head and Neck, Liver, and Stomach.Molecules (Basel, Switzerland) · 2021Article
- Review
- Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2020Article
- Article
- Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer.Infectious agents and cancer · 2020Review
- Sensitive detection of EBV microRNAs across cancer spectrum reveals association with decreased survival in adult acute myelocytic leukemia.Scientific reports · 2019Article
- The Function and Therapeutic Potential of Epstein-Barr Virus-Encoded MicroRNAs in Cancer.Molecular therapy. Nucleic acids · 2019Review
- Key questions about the checkpoint blockade-are microRNAs an answer?Cancer biology & medicine · 2018Article
- MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment.Frontiers in immunology · 2018Review
- Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.Cancer cell international · 2018Review
- Gene sharing between Epstein-Barr virus and human immune response genes.Immunologic research · 2017Review
- Pathogenic Role of Exosomes in Epstein-Barr Virus (EBV)-Associated Cancers.International journal of biological sciences · 2017Review
- Genetics and Molecular Biology of Epstein-Barr Virus-Encoded BART MicroRNA: A Paradigm for Viral Modulation of Host Immune Response Genes and Genome Stability.Journal of immunology research · 2017Review
- Assessment of Epstein-Barr virus nucleic acids in gastric but not in breast cancer by next-generation sequencing of pooled Mexican samples.Memorias do Instituto Oswaldo Cruz · 2016Article
- Discriminating between Terminal- and Non-Terminal Respiratory Unit-Type Lung Adenocarcinoma Based on MicroRNA Profiles.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Cancer Genome Atlas (TCGA) microRNA (miRNA) initiative has revealed a pivotal role for miRNAs in cancer. Utilizing the TCGA raw data, we performed the first mapping of viral miRNA sequences within cancer and adjacent normal tissues. Results were integrated with TCGA RNA-seq to link the expression of viral miRNAs to the phenotype. Using clinical data and viral miRNA mapping results we also performed outcome analysis. Three lines of evidence lend credence to an active role of viral miRNAs in solid malignancies. First, expression of viral miRNA is consistently higher in cancerous compared to adjacent noncancerous tissues. Second, viral miRNA expression is associated with significantly worse clinical outcome among patients with early stage malignancy. These patients are also featured by increased expression of PD1/PD-L1, a pathway implicated in tumors escaping immune destruction. Finally, a particular cluster of EBV-miRNA (miR-BART2, miR-BART4, miR-BART5, miR-BART18, and miR-BART22) is associated with expression of cytokines known to inhibit host response to cancer. Quantification of specific viral miRNAs may help identify patients who are at risk of poor outcome. These patients may be candidates for novel therapeutic strategies incorporating antiviral agents and/or inhibitors of the PD-1/PD-L1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.